• HTA97 Impact of Additive PICOs in a European Joint Health Technology Assessment. a Hypothetical Case Study in Lung Cancer

    Dec 1, 2022, 00:00

  • P62 Parametric Survival Extrapolations of Larotrectinib and Entrectinib for NTRK Fusion Cancers

    Dec 1, 2022, 00:00

  • EE606 Cost-Effectiveness Analysis of a Potential Vaccine to Prevent Colonization by Helicobacter Pylori in the South-European Context

    Dec 1, 2022, 00:00

  • HTA8 The Catalan Health Service, An Example Where Patients Have Full Medicine Appraisal and Decision-Making Representation

    Dec 1, 2022, 00:00

  • PCR248 The Value of Clinical Functions in Neurorehabilitation - Can a Value Function Be Derived From a Generic Instrument?

    Dec 1, 2022, 00:00

  • EE68 Burden of Hospitalization, Costs and Co-Morbidities in Patients With Chronic Lymphocytic Leukemia: Analysis of Real-World Evidence Using National In-Patient Hospital Database

    Dec 1, 2022, 00:00

  • EE440 Cost-Effectiveness Analysis of 4% Fluorouracil for the Treatment of Actinic Keratosis in the Czech Republic

    Dec 1, 2022, 00:00

  • EE559 The Economic Impact of Reducing Bleeding With Emicizumab in Patients With Hemophilia A and Factor VIII Inhibitors – Brazilian Case

    Dec 1, 2022, 00:00

  • MSR103 Comparison of Three Indirect Overall Survival (OS) Modeling Approaches in Predicting Long-Term OS Benefit in Randomized Controlled Trials: A Case Study From the Relativity-047 Study

    Dec 1, 2022, 00:00

  • EE526 Public Health Impact and Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States

    Dec 1, 2022, 00:00

  • MSR8 Challenges of Network Meta-Analysis for Safety Outcomes: The Analysis of Tirbanibulin Against Common Treatments in Europe for Actinic Keratosis

    Dec 1, 2022, 00:00

  • EE360 Health Care Resource Utilization With Asciminib and Bosutinib Among Adults With Chronic Myeloid Leukemia in Chronic Phase Previously Treated With ≥2 Tyrosine Kinase Inhibitors: Week 48 and Week 96 Results From ASCEMBL Trial

    Dec 1, 2022, 00:00

  • MSR63 Barriers to Improving the Digital Performance of the Pharmaceutical Industry

    Dec 1, 2022, 00:00

  • HTA213 Seven Years of HTA in Singapore: Practices and Key Drivers

    Dec 1, 2022, 00:00

  • EE601 Age-Related Macular Degeneration: The Actual Burden and the Possible Saving of an Improved Management in Italy

    Dec 1, 2022, 00:00

  • EE255 Budget Impact Analysis of the Introduction of a Prognostic Prostate Genomic Biomarker Cancer Test in the Management of Localized Prostate Cancer Patients for Greece

    Dec 1, 2022, 00:00

  • EPH150 The Psychological Impacts of COVID -19 as a Social Influence Parameter During the Pandemic

    Dec 1, 2022, 00:00

  • EPH78 In the Crosshairs: Eating and Fluid Consumption Habits of the Students of the International Bachelor Program at the University of Pécs

    Dec 1, 2022, 00:00

  • PCR19 SARS-COV-1 Omicron BA.1 Associated Impact on Quality of Life and Medication Adherence of Multiple Myeloma Patients Treated With Thalidomide or Its Analogues Plus Dexamethasone 1JAN-31MAR2022

    Dec 1, 2022, 00:00

  • EE594 The Cost of Care Among Infantile and Child Spinal Muscular Atrophy Patients: RWE from a Large Claims Database

    Dec 1, 2022, 00:00

  • PCR226 Patient and Public Involvement in Research: Reflections on Open Health Collaborations

    Dec 1, 2022, 00:00

  • EE281 Freestyle Libre 2 Flash Glucose Monitoring System: Budget Impact and Cost-Utility Analyses in Type 1 Diabetes From the Italian NHS Perspective

    Dec 1, 2022, 00:00

  • CO150 Characteristics, Healthcare Resource Utilization and Costs Among Medicaid-Insured Adults With Hepatitis Delta Virus: An Analysis of US All-Payer Medical and Pharmacy Claims Data

    Dec 1, 2022, 00:00

  • EE16 Cost-Effectiveness of Cannabidiol Add-on Therapy Versus Placebo for the Treatment of Seizures in Tuberous Sclerosis Complex

    Dec 1, 2022, 00:00

  • MSR56 Measuring HIV Health Management Efficiency Among Health Insurers in Colombia Using Data Envelopment Analysis

    Dec 1, 2022, 00:00

  • EPH204 What Doesn't Kill You: Re-Evaluating Our Approach to High Burden, Low Mortality Chronic Diseases With a Focus on Migraine and Multiple Sclerosis

    Dec 1, 2022, 00:00

  • EE304 Cost-Effectiveness of Volume Computed Tomography in Lung Cancer Screening: A Cohort Simulation Based on Nelson Study Outcomes

    Dec 1, 2022, 00:00

  • PCR67 A Systematic Literature Review of Health-Related Quality of Life of Patients With Advanced Esophageal Cancer

    Dec 1, 2022, 00:00

  • RWD26 Real World Evidence Studies Presented in ISPOR 2022: A Descriptive Analysis of Research Posters

    Dec 1, 2022, 00:00

  • EE501 Making R-Based Economic Models Even Shinier With Web-Based Interfaces

    Dec 1, 2022, 00:00

  • EE511 Cost Effectiveness of Uroprotective Agents for Cyclophosphamide and Ifosfamide Induced Hemorrhagic Cystitis in Childhood Cancers

    Dec 1, 2022, 00:00

  • EE474 Budget Impact Analysis of Perioperative Nutrition in Surgical Oncology Patients

    Dec 1, 2022, 00:00

  • CO124 Indirect Comparison of Efficacy and Safety for Aumolertinib vs Osimertinib in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2022, 00:00

  • EE163 Analysis of Healthcare Resource Use of the Robotic Surgery System for Rectal Cancer in Japan

    Dec 1, 2022, 00:00

  • EE266 A Review on the Economic Evaluation of Infertility Pharmacologic Agents in North America and European Countries

    Dec 1, 2022, 00:00

  • HPR192 An Assessment of the Impact of the Three Memorandum Policies on Health Outcomes of the Greek Population

    Dec 1, 2022, 00:00

  • HTA51 Challenges and Opportunities of Health Technology Assessment in Older Adult Immunization

    Dec 1, 2022, 00:00

  • EE592 Long-Term Health and Economic Benefits of Switching to Tenofovir Alafenamide Versus Continuing on Entecavir in Chronic Hepatitis B Patients With Low-Level Viremia in Saudi Arabia

    Dec 1, 2022, 00:00

  • HPR200 The Impact of Community Pharmacies on Regional Equity in Access to Professional Rapid Antigen Testing for SARS-COV-2 in Portugal

    Dec 1, 2022, 00:00

  • PCR139 Qualitative Approaches Using Global Assessments to Support Meaningful Within-Person Change (MWPC) Estimates for Patient-Reported Outcome (PRO) Questionnaires in Regulated Clinical Trials

    Dec 1, 2022, 00:00

  • SA58 Real-World Outcomes for the Treatment of Relapsed/Refractory Multiple Myeloma With Daratumumab: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • EE111 Cost-Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Chronic Heart Failure Irrespective of Left-Ventricle Ejection Fraction in the Netherlands

    Dec 1, 2022, 00:00

  • HTA254 Roadblocks to Effective Patient Engagement in Health Technology Assessment in Europe: A Review of Patient-Perceived Challenges

    Dec 1, 2022, 00:00

  • EE516 Budget-Impact Model of Adalimumab-Biosimilar Sandoz in the Management of Autoimmune Diseases in the Middle East

    Dec 1, 2022, 00:00

  • MSR53 A Review of Methods for Estimating Individual Treatment Effect From Real World Data for Use in Health Technology Assessment: Separating Hype From Reality

    Dec 1, 2022, 00:00

  • HTA39 Estimating the True Cost of Weight-Based Chemotherapy

    Dec 1, 2022, 00:00

  • RWD143 Synthetic Health Data at a Glan Striking a Balance between Privacy and Utility

    Dec 1, 2022, 00:00

  • EPH95 Costs of Ruling Out Coronary Heart Disease (CHD) in German Outpatient Service

    Dec 1, 2022, 00:00

  • MSR17 Modernizing Pressure Injury Risk Assessment in the ICU in the COVID Era: Ensemble Super-Learning and Explainable AI

    Dec 1, 2022, 00:00

  • MSR18 Modeling and Comparison of Non-Disease-Related Survival (NDRS) Using Local Lifetables and Reported Trial Data: A Case Study From Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma (MIUC)

    Dec 1, 2022, 00:00

  • RWD107 Better Use of Real-World Data Through Predictive Analytics: A Knowledge-to-Wisdom Conceptual Framework for Evidence-Based Practice

    Dec 1, 2022, 00:00

  • SA47 Clinical Effectiveness of Osimertinib in Non-Small Cell Lung Cancer Patients With EGFR Mutation Between Plasma and Tissue Re-Biopsy: A Systematic Review and Meta-Analysis of Real-World Evidence

    Dec 1, 2022, 00:00

  • EE506 Budget Impact Analysis of Dapagliflozin in the Treatment of Chronic Kidney Disease in Mexico

    Dec 1, 2022, 00:00

  • HPR60 A Review on Policies Adopted and Existing Drug Regulation Amended for Speedy Development of Vaccines in India

    Dec 1, 2022, 00:00

  • PCR121 Do Changes in Patient-Reported Outcomes Predict Overall Survival in Patients With Diffuse Large B-Cell Lymphoma?

    Dec 1, 2022, 00:00

  • HSD29 Factors Influencing Deprescribing Activities in the Management of Hospitalized Patients in Polytherapy

    Dec 1, 2022, 00:00

  • HPR24 Critical Analysis on Time-to-Reimbursement of Rare Disease Drugs: The Italian Case (AIFA Commissions 2018-2022)

    Dec 1, 2022, 00:00

  • HPR8 An Analysis of Risk Sharing Arrangements (RSAS) Between 2013 and 2021 in Australia

    Dec 1, 2022, 00:00

  • RWD128 Exploring the Burden of COVID-19 on Post-Traumatic Stress Disorder (PTSD) in Pre- and During-COVID-19 Pandemic Using Real-World Data

    Dec 1, 2022, 00:00

  • MT37 Comparative Analysis of Intra-Operative Transfusion Rates: Surgical Modality Comparison Using Japanese Real-World Database

    Dec 1, 2022, 00:00

  • HSD58 Country Differences in the Clinical Manifestations and Treatment Patterns of Patients With Eosinophilic Granulomatosis With Polyangiitis (EGPA): A European Perspective

    Dec 1, 2022, 00:00

  • EE58 Budget Impact Analysis of Minimally Invasive Techniques Against Abdominal Hysterectomy for Benign Gynaecological Conditions: A Spanish Hospital Perspective

    Dec 1, 2022, 00:00

  • EE445 Treatment Costs of Comorbidities in Patients With Peripheral Artery Disease in Turkiye

    Dec 1, 2022, 00:00

  • CO168 Adaptive Behaviors Over Time in Children and Young Adults With Classic Galactosemia

    Dec 1, 2022, 00:00

  • Methodological Statistical Research

    Dec 1, 2022, 00:00

  • EPH134 Economic and Utility Evidence for Metastatic Synovial Sarcoma and Myxoid Round Cell Liposarcoma: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • CO106 Impact of Phase Angle in Quality of Life and Mortality in Male With Head and Neck Cancer

    Dec 1, 2022, 00:00

  • EE258 A Methodological Foundation for the Creation of the Pharmaceutical RD Call Options Market

    Dec 1, 2022, 00:00

  • EE196 Updated Recommendations for Budget Impact Scale for HTA System Implementation in Ukraine

    Dec 1, 2022, 00:00

  • HSD104 Positions of SGLT2-Inhibitors in Treatment Algorithms for Heart Failure and Chronic Kidney Disease: Time to Recognise Their Value Beyond Type 2 Diabetes Management

    Dec 1, 2022, 00:00

  • HPR92 Analysis of Nutritional Supplements’ Price Change in Turkiye

    Dec 1, 2022, 00:00

  • HTA196 Influence of REvalMED Pilot Program on Drug Evaluations in Spain: An Analysis of Therapeutic Positioning Reports

    Dec 1, 2022, 00:00

  • EE269 Evolution and Implications of the Portuguese HTA Framework on Health Economics in Patients’ Access to Innovation

    Dec 1, 2022, 00:00

  • EE153 Cost From Asparaginase Utilization in the Treatment of Acute Lymphoblastic Leukaemia in Hong Kong Paediatrics Population According to CCCG-2015 Protocol

    Dec 1, 2022, 00:00

  • EE10 Cost-Effectiveness of Pembrolizumab Plus Chemotherapies for First-Line Treatment in Locally Advanced Unresectable or Metastatic Triple Negative Breast Cancer (MTNBC) in France

    Dec 1, 2022, 00:00

  • PCR186 The Life With Cystic Fibrosis: Socioeconomic Impact of the Disease on Patients and Their Caregivers in the Czech Republic

    Dec 1, 2022, 00:00

  • P67 Cumulative Effect of Depression on Health Worsening During The COVID-19 Lockdown Among Diabetic Patients in Europe

    Dec 1, 2022, 00:00

  • RWD95 Exploring the Burden of COVID-19 on Suicides and Suicidal Attempts (SSA) in Pre- and During-COVID-19 Pandemic Using Real-World Data

    Dec 1, 2022, 00:00

  • RWD35 Cost of Illness Study of Acromegaly in Bulgaria - A Real-World Data Analysis

    Dec 1, 2022, 00:00

  • P11 Informal Care Costs According to Age and Proximity to Death to Support Cost-Effectiveness Analyses

    Dec 1, 2022, 00:00

  • MSR71 Performance of AIC and BIC for the Extrapolation of Survival Data With Different Levels of Censoring

    Dec 1, 2022, 00:00

  • RWD47 Use of Radiotherapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in Italy: A Real-World Data Analysis

    Dec 1, 2022, 00:00

  • HTA225 A Review of External Evidence Used to Support Survival Extrapolation in Assessments of Cancer Drugs by the National Institute for Health and Care Excellence (NICE)

    Dec 1, 2022, 00:00

  • EE672 Cost-Effectiveness Evaluation of Human Papilloma Virus Test in Comparison With Cytology From the Chilean Public System Perspective

    Dec 1, 2022, 00:00

  • HPR107 Challenges and Opportunities of the German ‘Coverage with Evidence Development’ Scheme for New Medical Devices: A Mixed-Methods Study

    Dec 1, 2022, 00:00

  • OP12 Findings From the 2022 International Society for Pharmacoeconomics and Outcomes Research Student Benefit Survey

    Dec 1, 2022, 00:00

  • CO133 Analysing Phlebitis Associated With the Use of Peripheral Short Cannulas in an Emergency Department Setting

    Dec 1, 2022, 00:00

  • HTA49 Implementation of Equity as an Element of Value in Health Care Technology Assessments in Europe

    Dec 1, 2022, 00:00

  • RWD60 Exploring the Burden of COVID-19 on Eating Disorders Spectrum (Types of Eating Disorders) in Pre- and During-COVID-19 Pandemic Using Real-World Data

    Dec 1, 2022, 00:00

  • EE604 Cost-Benefit Analysis of the New Jersey Prescription Drug Monitoring Program

    Dec 1, 2022, 00:00

  • EE620 A Meta-Analysis of Bronchoscope Associated Cross-Infection and Early Cost-Effectiveness Analysis of Single-Use Compared to Reusable Flexible Bronchoscopes in the Bronchoscopy Suite of American Academic Institutions

    Dec 1, 2022, 00:00

  • EE324 Cost-Effectiveness analysis of Atezolizumab as Adjuvant Treatment of Patients With Stage II-IIIA Non-Small Cell Lung Cancer, With Pd-L1≥50% of Tumor Cells, in France

    Dec 1, 2022, 00:00

  • RWD71 Is the Real-World Evidence for Effectiveness and Safety of Biosimilars Vis-à-vis Originators FDA Compliant?

    Dec 1, 2022, 00:00

  • EE490 Attributable Cost of Adult Respiratory Syncytial Virus Illness Beyond the Acute Phase

    Dec 1, 2022, 00:00

  • PCR26 Assessing the Content Validity of Preference-Based Measures in Cancer

    Dec 1, 2022, 00:00

  • HPR186 The Optimized Patient Treatment Initiative (OPT-IN): Choosing the Right Therapy, for the Right Patient, at the Right Time

    Dec 1, 2022, 00:00

  • HTA42 Use of Health-Related Quality of Life (HRQoL) Outcomes/Patient-Reported Outcomes (PROs) in Rare Hematological Disease (RHD) Health Technology Assessment (HTA) Submissions

    Dec 1, 2022, 00:00

  • CO51 Efficacy and Safety of Vonoprazan Triple Therapy (Vonoprazan, Amoxicillin, Clarithromycin) in Patients With Helicobacter Pylori Infection: Systematic Review Meta-Analysis of Randomized Controlled Trials

    Dec 1, 2022, 00:00

  • EE60 An Economic Evaluation of Introducing Ferric Carboxymaltose for the Treatment of Iron Deficiency in Patients With Heart Failure From the Perspective of Healthcare Payers in Sweden, Germany, France, Poland and Spain

    Dec 1, 2022, 00:00

  • EE149 Cost-Effectiveness of Cladribine Tablets and Dimethyl Fumarate in the Treatment of Relapsing Remitting Multiple Sclerosis in Spain

    Dec 1, 2022, 00:00

  • EE446 Cost-Effectiveness of Pneumococcal Vaccination for at-Risk and High-Risk Elderly in Limited Resource Context: Lessons Learned From Thailand

    Dec 1, 2022, 00:00

  • HTA152 Practical Challenges of Implementing a New Patient-Reported Outcome (PRO) in Oncology Under the German Pharmaceutical Market Restructuring Act (AMNOG) - Results From a Qualitative Focus Group Study

    Dec 1, 2022, 00:00

  • EE637 Cost of Follow-Up in Patients With Heterozygous Familial Hypercholesterolemia in Spain: Results From the Reality Study

    Dec 1, 2022, 00:00

  • EPH20 Real-World Effectiveness of Palbociclib With Concomitant Proton Pump Inhibitor in Patients With Breast Cancer in South Korea: A Retrospective Cohort Study

    Dec 1, 2022, 00:00

  • EPH135 A Cross Sectional Survey of Student Pharmacists’ Vaccine Hesitancy Perceptions at a United States College of Pharmacy

    Dec 1, 2022, 00:00

  • HTA211 Are Surrogate Endpoints a Way Forward in Non-Small Cell Lung Cancer (NSCLC)? A Comparison of HTA Outcomes Across Germany, France, and the UK

    Dec 1, 2022, 00:00

  • EE485 Budget Impact Model (BIM) of the Newly Proposed Value-Based Positive Airway Pressure (PAP) Therapy Based on Telemonitoring in Patients With Obstructive Sleep Apnea (OSA) in Spain.

    Dec 1, 2022, 00:00

  • PCR89 Qualitative Research to Understand the Lived Experience of Patients with Dry Eye Disease (DED), Meibomian Gland Dysfunction (MGD), and Sjogren's Syndrome Dry Eye Disease (SS-DED)

    Dec 1, 2022, 00:00

  • PCR165 Patient Reported Outcomes Measures for Patients With Rheumatoid Arthritis: Patterns of Use Among Spanish Rheumatologists and Barriers for Their Implementation in Routine Care

    Dec 1, 2022, 00:00

  • EE53 The Net Monetary Benefit of Introducing Sodium-Glucose Cotransporter-2 Inhibitors in Middle-Income Countries

    Dec 1, 2022, 00:00

  • SA81 Feasibility and Challenges of Virtual Time Trade-Off Interviews: The Case of the EQ-5D-3L Valuation Study in Jordan

    Dec 1, 2022, 00:00

  • HTA77 The Use and Acceptability of External Comparator Studies to Support Hemato-Oncology Single-Arm Trial Submissions to Health Technology Assessment Bodies

    Dec 1, 2022, 00:00

  • EE499 Challenges of Health Economic Evaluations Alongside Innovative Clinical Trial Designs in Precision Oncology – Results of a Literature Review

    Dec 1, 2022, 00:00

  • RWD166 Prevalence of PD-L1 and Other Selected Biomarkers in Advanced Urothelial and Esophageal Carcinoma and Advanced Head and Neck Squamous Cell Carcinoma in Two Reference Institutions of Colombia

    Dec 1, 2022, 00:00

  • EPH168 Assessment of the Prevalence of Emotional Burnout Among Medical Workers in the Republic of Kazakhstan

    Dec 1, 2022, 00:00

  • EE329 Public Health and Economic Impact of a Gender-Neutral Quadrivalent Human Papillomavirus Vaccination Program in El Salvador

    Dec 1, 2022, 00:00

  • HPR126 Lessons From the US and EU: How China Can Avoid Missteps in Biosimilar Adoption

    Dec 1, 2022, 00:00

  • HTA59 Association Between Information Sources of Manufacturer-Proposed Utility Values and the NICE Technology Appraisal Committee's Acceptance

    Dec 1, 2022, 00:00

  • P44 Review of Methods Used to Estimate Treatment Effects Against Relevant Comparators Using Evidence From Single-Arm Studies in NICE Single Technology Appraisals

    Dec 1, 2022, 00:00

  • RWD67 Association of COVID-19 With Venous Thrombosis and Arterial Thrombosis

    Dec 1, 2022, 00:00

  • PCR79 Differences in the Health-Related Quality of Life Between Diabetic Patients With and Those Without Comorbidities in South Korea

    Dec 1, 2022, 00:00

  • EE525 The Economic Value of Insulin Glargine 300 U/Ml (Gla-300) in People ≥18 Years of Age With Type 2 Diabetes Mellitus: A Value-Based Economic Model From a U.S. Payer Perspective

    Dec 1, 2022, 00:00

  • HSD36 Generic Penetration in the Market for Antidiabetics, Lipid Modifying Agents and Psychoeleptics/Psychoanaleptics: A Comparative Analysis of Data From 18 European Markets

    Dec 1, 2022, 00:00

  • HTA194 A Review of Oncology Submissions to NICE to See How Often Disease-Specific Quality of Life Data Have Been Accepted

    Dec 1, 2022, 00:00

  • EE50 A Cost-Consequence Model of Using the 21-Gene Breast Recurrence Score Assay to Identify Patients With Early-Stage Node-Positive Breast Cancer Who Benefit From Adjuvant Chemotherapy in the Netherlands

    Dec 1, 2022, 00:00

  • EE353 Resource Utilisation and Healthcare Costs Among Patients With Major Depression and Active Suicidal Ideation With Intent in Italy: Initial Findings From the Arianna Observational Substudy

    Dec 1, 2022, 00:00

  • HPR129 Reimbursement Status of European Medicines Agency Authorised Drugs in Spain

    Dec 1, 2022, 00:00

  • CO174 A Comparison of Stan Versus WinBUGS Software for Conducting Bayesian Network Meta-Analyses of Binary Outcomes

    Dec 1, 2022, 00:00

  • HTA141 Does NICE’s New Severity Modifier Capture the Value of Treatments for Long-Term Progressive Diseases? A Retrospective Analysis of Past Appraisals in Multiple Sclerosis

    Dec 1, 2022, 00:00

  • PCR158 Patient Reported Outcomes (PRO) From Ongoing Phase 2 Registrational Trial of Repotrectinib in Patients With ROS1-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (TRIDENT-1)

    Dec 1, 2022, 00:00

  • PCR117 Achieving Stringent Clinical Disease Control Criteria Is Associated With Improved Quality of Life Measures in Patients With Active Psoriatic Arthritis: Results From Two Phase 3 Randomised, Placebo-Controlled Studies

    Dec 1, 2022, 00:00

  • RWD152 Hospital Outcomes and Costs for Prostate Cancer Patients With Comorbid Heart Failure by Age Group: An Analysis of the U.S. Nationwide Inpatient Sample

    Dec 1, 2022, 00:00

  • EE356 Budget Impact of Extracorporeal Photopheresis for Treatment of Chronic Lung Allograft Dysfunction Following Lung Transplantation in Switzerland – Results of a Single-Center Retrospective Chart Review

    Dec 1, 2022, 00:00

  • PCR144 International Adaptation and Linguistic Validation of the Hypoparathyroidism Daily Diary of Symptom Experience (HPT-DD-SE) and the Hypoparathyroidism Life Impact Questionnaire (HPT-LIQ)

    Dec 1, 2022, 00:00

  • EE31 Costs of Gist and Non-GIST STSs in Turkiye: A Delphi Panel Study

    Dec 1, 2022, 00:00

  • MSR129 Limitations and Opportunities for Identifying Outcome Prognostic Factors in the Context of Small Samples

    Dec 1, 2022, 00:00

  • HSD26 Real-World Patterns of Care and Outcomes Among Advanced Cervical Cancer Patients in England: Retrospective Analysis of the NCRAS Datasets, 2012-2019

    Dec 1, 2022, 00:00

  • MSR24 Can Artificial Intelligence Separate the Wheat From the Chaff in Systematic Reviews of Health Economic Papers?

    Dec 1, 2022, 00:00

  • PCR166 Online Elicitation of Personal Utility Functions (OPUF) – An Open, Modular Health Valuation Platform

    Dec 1, 2022, 00:00

  • EPH65 Assessment of Enzyme Preparations Consumption in Ukraine in Comparison With Other Countries of the World

    Dec 1, 2022, 00:00

  • EE553 Hospitalisation and Healthcare Costs in Adults with Systemic Lupus Erythematosus in Sweden: A Real-World Observational Cohort Study

    Dec 1, 2022, 00:00

  • PCR192 Treatment Burden and Its Relationship With Health-Related Quality of Life, Work Productivity and Activity Impairment in Adults With Severe Non-Inhibitor Hemophilia A in the United States: Data Analysis From the CHESS US+ Study

    Dec 1, 2022, 00:00

  • PCR208 Developing a Conceptual Framework for Socioeconomic Impact Research in European Cancer Patients - A 'Best-Fit' Framework Synthesis

    Dec 1, 2022, 00:00

  • CO113 Systematic Review and Network Meta-Analysis of Durability of Faricimab in Neovascular Age-Related Macular Degeneration

    Dec 1, 2022, 00:00

  • EE636 Cost of Follow-Up After a Peripheral Arterial Event in Patients With Atherosclerotic Cardiovascular Disease in Spain: Results From the Reality Study

    Dec 1, 2022, 00:00

  • HTA64 A Retrospective Review of NICE Appraisals From 2017-2022 to Investigate the Impact of the New Severity Modifier on Cost-Effectiveness Thresholds Across Multiple Therapy Areas

    Dec 1, 2022, 00:00

  • HTA238 Uncovering the Hidden Rare Disease Gap Within NICE Appraisals

    Dec 1, 2022, 00:00

  • EE380 The Health and Economic Impact of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT2IS) in the Netherlands

    Dec 1, 2022, 00:00

  • PCR48 Meaningful Change Is a Perception, Not Only a Number: A Review of Qualitative Interviews Exploring Meaningful Changes in Symptoms

    Dec 1, 2022, 00:00

  • CO108 Project Ideate: Designing a Robust Methodology for an Experimental, Retrospective Outcome-Based Agreement in a Breast Cancer Treatment

    Dec 1, 2022, 00:00

  • HTA247 Real-World Evidence in Multiple Sclerosis (MS): HTA Decision-Making Influencer or Not?

    Dec 1, 2022, 00:00

  • MSR44 An Extended Simulated Treatment Comparison Approach Accounting for Unobserved Confounding in Indirect Comparisons for Single-Arm Trials

    Dec 1, 2022, 00:00

  • RWD63 Comparison of Certified Secure Processing Environments (SPE) – Novel Platforms for Collection, Augmentation, Structuring, Transfer, Management, Analysis, Sharing, Reporting, and Storage of Sensitive Data?

    Dec 1, 2022, 00:00

  • EE225 What Is the Economic Impact of Delaying Kidney Replacement Therapy Through Ketoanalogue-Supplemented Low Protein Diet in Advanced Chronic Kidney Disease?

    Dec 1, 2022, 00:00

  • CO5 The Challenges of Generating Patient-Relevant Outcomes and Other Evidence Sufficient to Satisfy European HTA Bodies in Acute Conditions Managed in the ICU

    Dec 1, 2022, 00:00

  • MSR82 Dealing With Non-Comparative Data: Proposed Alternatives and Considerations to Conduct Indirect Treatment Comparisons (ITCs)

    Dec 1, 2022, 00:00

  • EE320 Humanistic and Economic Burden of Advanced Hepatocellular Carcinoma: A Systematic Review

    Dec 1, 2022, 00:00

  • HTA17 Cost-Effectiveness Analysis of Tocilizumab for The Treatment of COVID-19 in Hospitalised Patients on Corticosteroids, From the Italian NHS Perspective

    Dec 1, 2022, 00:00

  • CO35 Project Ideate: Modelling Payments and Volatility of an Experimental, Retrospective Outcome-Based Agreement for a Breast Cancer Treatment in Wales, 2018-2020

    Dec 1, 2022, 00:00

  • PCR169 Patient Involvement in Regulatory and HTA Processess: A Call for Enhanced Alignment

    Dec 1, 2022, 00:00

  • EE148 Canadian Cost-Effectiveness Analysis of Deferiprone Compared to Deferoxamine and Deferasirox for the Treatment of Iron Overload in Patients With Sickle Cell Disease and Other Anemias

    Dec 1, 2022, 00:00

  • RWD22 Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Management in Belgium: A Longitudinal Pharmacy Database Study

    Dec 1, 2022, 00:00

  • EE487 Quantifying the Economic Burden of Obstructive Hypertrophic Cardiomyopathy (HCM) in the UK

    Dec 1, 2022, 00:00

  • EPH80 Influence of Socio-Demographic Factors on Internet Addiction in Students of Professional Courses in Dakshina Kannada District, Karnataka: A Cross-Sectional Study

    Dec 1, 2022, 00:00

  • CO132 Focuses on the Prevalence and Impact of Metabolic Syndrome on the Outcome of Patients With Acute Coronary Syndrome in Iraq and Hungary

    Dec 1, 2022, 00:00

  • EE632 Winning the COVID-19 Vaccine Ra How to Launch a Premium Priced COVID-19 Vaccine in a Competitive and Saturated Cost-Effectiveness Market

    Dec 1, 2022, 00:00

  • EPH10 Social Determinants of Health in Swedish Administrative Data – Who, What, and How Often?

    Dec 1, 2022, 00:00

  • EE462 Cost-Effectiveness of Nivolumab for the Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma Patients With High Risk of Recurrence and Tumor Cell Pd-L1 Expression ≥ 1% in Sweden

    Dec 1, 2022, 00:00

  • HTA185 HTA Indexing in the Purpose-Built INAHTA and CRD HTA Databases

    Dec 1, 2022, 00:00

  • EE15 Cost-Consequence Analysis of Ofatumumab in Comparison With Other Disease-Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

    Dec 1, 2022, 00:00

  • P48 Evaluating the Clinical, Economic, and Societal Value of Rapid Diagnostic Testing in Emerging Markets: A Systematic Literature Review Assessing Infectious Diseases

    Dec 1, 2022, 00:00

  • HTA103 Revalmed – What Is the Potential Impact of This New Process on the Spanish Market Access System?

    Dec 1, 2022, 00:00

  • RWD38 Genetic Mutational Testing in CLL Patients in the Routine Care of Eight EU Member States

    Dec 1, 2022, 00:00

  • HSD37 Information Seeking Behaviour of the Hungarian Population Regarding Antibiotics and Common Infectious Ailments: An Infodemiological and Thematic Analysis Using Google TRENDSTM

    Dec 1, 2022, 00:00

  • SA9 RWE Pathway: The State-of-the-Art of Patient Registries in Portugal

    Dec 1, 2022, 00:00

  • EE565 Cost-Utility Analysis of Dupilumab in Adults and Adolescents With Uncontrolled Persistent Severe Asthma in Portugal

    Dec 1, 2022, 00:00

  • Disclosure Information

    Dec 1, 2022, 00:00

  • RWD14 Approaches to Selecting ‘Time Zero’ in External Control Arms with Multiple Potential Entry Points: A Simulation Study of Eight Approaches

    Dec 1, 2022, 00:00

  • EE309 Impact of Differential Baseline Utility Values: Atopic Dermatitis

    Dec 1, 2022, 00:00

  • RWD148 Patient Reported Outcomes With Chemotherapy of Breast Cancer: An Analysis of Breast Cancer Registry Publications Between 2012-2022

    Dec 1, 2022, 00:00

  • EPH91 Association Between Mental Disorders and COVID-19 Outcomes in Hospitalized Patients in Fran A Retrospective Nationwide Population-Based Study

    Dec 1, 2022, 00:00

  • HTA76 Clinical Expert Opinion in Health Technology Assessment Submissions to a National HTA Agency in Ireland

    Dec 1, 2022, 00:00

  • HTA174 Analysis of NICE Fast Track Appraisals: What Are the Key Characteristics for Success?

    Dec 1, 2022, 00:00

  • RWD82 Influence of the COVID-19 Pandemic on Patients Receiving Oral Anticoagulants for the Treatment of Non-Valvular Atrial Fibrillation

    Dec 1, 2022, 00:00

  • MSR96 A Methodological Study to Compare Alternative Modes of Administration for Undertaking Preference-Elicitation Studies

    Dec 1, 2022, 00:00

  • HPR178 Evaluation of Total Health Expenditures in OECD Countries for the Years 2000, 2010 and 2019

    Dec 1, 2022, 00:00

  • EE387 Major Ischemic or Hemorrhagic Events and Associated Costs Among Anticoagulated Patients With Non-Valvular Atrial Fibrillation in Switzerland

    Dec 1, 2022, 00:00

  • EE297 A Cost-of-Illness Study of the Economic Burden of Obsessive-Compulsive Disorder in the United Kingdom

    Dec 1, 2022, 00:00

  • CO121 Treat-and-Extend Versus As-Needed Regimen in Neovascular Age-Related Macular Degeneration: 1-Year Findings From a Network Meta-Analysis

    Dec 1, 2022, 00:00

  • P58 Predicting the Risk of Stroke Using Machine Learning on a Large Administrative Health Database

    Dec 1, 2022, 00:00

  • P55 Creating a Web-Based Interactive Map Visualising the Geographic Variations of the Burden of Diabetes to Inform Policymaking: An Example From Tasmania, Australia

    Dec 1, 2022, 00:00

  • EE375 Cost-Effectiveness Analysis of the Oncotype DX® Test to Reduce Under-Treatment in Patients With HR+/HER2- Node Negative Early-Stage Breast Cancer and Grade 2 T1C Tumours

    Dec 1, 2022, 00:00

  • EE69 Cost Utility and Budget Impact Analyses of Closed Loop Upper Airway Stimulation (UAS) for the Treatment of Moderate to Severe Obstructive Sleep Apnea From an Australian Health Care System Perspective

    Dec 1, 2022, 00:00

  • HPR182 What Impact Did China's National Volume-Based Procurement Have on Drug Use Pattern and Clinical Benefit? Taking Amlodipine as an Example

    Dec 1, 2022, 00:00

  • PCR200 Measuring the Burden of Alopecia Areata With the European Quality of Life-5 Dimensions (EQ-5D): Results From a Real-World Survey in 5 European Countries

    Dec 1, 2022, 00:00

  • EE528 Resource Use and Costs Associated With Computerized Decision Support System for Managing Patients With Atrial Fibrillation

    Dec 1, 2022, 00:00

  • EE613 Burden of Hospitalization, Costs and Co-Morbidities in Medicare Patients With Chronic Graft Versus Host Disease: Analysis of National In-Patient Hospital Database

    Dec 1, 2022, 00:00

  • HPR17 Changing Landscape of Orphan Drug Reimbursement - Evidence From EU-4 and England

    Dec 1, 2022, 00:00

  • EE616 Management of Chronic Lymphocytic Leukemia: What Impact on Consumption and Expenditure?

    Dec 1, 2022, 00:00

  • HPR56 The Rise of Real-World Evidence (RWE) in EU Marketing Authorization Decisions – Past, Present, and Future

    Dec 1, 2022, 00:00

  • HPR116 The Impact of Policy Measures to Increase the Uptake of Biosimilar Medicines in Belgium: A Nationwide Interrupted Time Series Analysis

    Dec 1, 2022, 00:00

  • HPR102 Exploring Alternative Financing Models and Early Access Schemes for Orphan Drugs: A Belgian Case Study

    Dec 1, 2022, 00:00

  • EE332 Cost-Effectiveness Analysis of Using a Smartphone Application to Improve Timely Vaccination Among Children in the Zaatari Refugees Camp, Jordan

    Dec 1, 2022, 00:00

  • P63 Patient-Reported Outcomes Following Treatment with Vimseltinib for Tenosynovial Giant Cell Tumour in a Phase 2 Expansion Study

    Dec 1, 2022, 00:00

  • EE140 The Opportunity Cost of Managing Toric IOL Rotation Cases for a Private Cataract Surgery Centre in India: A Decision-Analytic Model Comparing Three Toric IOLs

    Dec 1, 2022, 00:00

  • EE279 Cost-Utility Analysis of Lower or Higher Oxygenation Targets for Acute Hypoxaemic Respiratory Failure – A Registry-Based Secondary Analysis of the Randomised Hot-ICU Trial

    Dec 1, 2022, 00:00

  • HTA166 How Successful Has the Technical Engagement Phase of NICE Appraisals Been in Resolving Issues?

    Dec 1, 2022, 00:00

  • HSD8 Cancer Survivorship Surveillance Patterns Among Earlier-Staged Lung Cancer (LC) Patients

    Dec 1, 2022, 00:00

  • HSD38 Assessing the Changes of Health Spa Demand in Hungary Between 2012 and 2019

    Dec 1, 2022, 00:00

  • CO63 Platinum Free-Interval in Patients With Ovarian Cancer Across an Argentinian Database: OCEANIA Real-World Study

    Dec 1, 2022, 00:00

  • EPH207 Epidemiology of Hospital Malnutrition With a Focus on Hospital Wards Where Malnutrition Is a Serious Problem

    Dec 1, 2022, 00:00

  • EE188 Health and Economic Impact of 23-Valent Pneumococcal Polysaccharide Vaccine in the Older Adult Immunization Program in Mexico

    Dec 1, 2022, 00:00

  • CO66 Survival of Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib in France During 2009-2018: Potentialities and Limitations of Model Adjustment in the SNDS French Hospital and Claim Database

    Dec 1, 2022, 00:00

  • RWD109 The Burden of R/R DLBCL in Finland: PFS of The First-Line Immunochemotherapy and HCRU of The Patients Diagnosed in 2015–2017 in The Hospital District of Southwest Finland

    Dec 1, 2022, 00:00

  • EE367 Budget Impact Analysis of Transcatheter Aortic Valve Replacement in Low, Intermediate, and High-Risk Patients With Severe Aortic Stenosis in Saudi Arabia

    Dec 1, 2022, 00:00

  • MSR134 Optimizing Fractional Polynomials by Using Variable Powers

    Dec 1, 2022, 00:00

  • HTA45 Uncertainty Regarding the Long-Term Effectiveness of New Therapies in Health Technology Assessment

    Dec 1, 2022, 00:00

  • PCR10 Qualitative Analysis of Patient Characters, Interviews on the Burden of Neuronopathic Gaucher Disease in Japan

    Dec 1, 2022, 00:00

  • EE543 Budget Impact Analysis of Gaucher Disease Pharmacologic Treatment in Colombia

    Dec 1, 2022, 00:00

  • EE336 Budget Impact Analysis of Zanubrutinib for Patients With Treatment-Naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the United States

    Dec 1, 2022, 00:00

  • EE323 Cost-Utility Analysis of Polygenic Risk Score in the Prevention of Type 2 Diabetes – An Object-Oriented Individual-Level Model With Probabilistic Sensitivity Analysis

    Dec 1, 2022, 00:00

  • CO67 Tafasitamab Plus Lenalidomide (TAFA+LEN) Versus Pola-BR, R2, and CAR-T in Non-Transplant Eligible (NTE) Relapsed/Refractory (R/R) DLBCL: A Post Hoc Analysis of the RE-MIND2 Study Comparing Multiple Cohort-Balancing Approaches

    Dec 1, 2022, 00:00

  • PCR205 Use of the Patient-Reported Outcomes Measurement Information System (PROMIS) in Rare Disease Clinical Trials

    Dec 1, 2022, 00:00

  • HTA129 The Evolution of Cost Comparison at NICE: What Can We Learn From Fast-Track Appraisals?

    Dec 1, 2022, 00:00

  • HTA156 Analysis of the Early Access Reform and Trends Observed in the Evaluation by the HAS

    Dec 1, 2022, 00:00

  • HTA134 Current and Future Trends in PR Decisions of Oncology and Onco-Hematology Drugs in Spain: A Retrospective and Forum Discussion Study

    Dec 1, 2022, 00:00

  • MSR98 Incorporating Covariates in Healthcare Decision-Making: Empirical Application of Methods in a Cost-Effectiveness Model for IVIG in Severe Sepsis

    Dec 1, 2022, 00:00

  • PCR69 Rheumatologists´ Perspective on Patient Reported Outcomes to Promote Shared Decision-Making in Patients With Rheumatoid Arthritis

    Dec 1, 2022, 00:00

  • EE655 Potential Solutions for the Cost-Effectiveness Paradox of Improving Carer Quality-of-Life in Terminal Conditions

    Dec 1, 2022, 00:00

  • PCR124 First-Line Treatment Patterns Among Patients With Locally Advanced or Metastatic Urothelial Cancer (la/mUC): A Systematic Literature Review

    Dec 1, 2022, 00:00

  • MSR70 A Head-to-Head Comparison of the EQ-5D-5L and 15D Descriptive Systems and Index Scores in a General Population Sample

    Dec 1, 2022, 00:00

  • HSD56 Assessing Effects of the IEHTC Program on Clinical Outcomes and Cost of Care in a Healthcare Provider Shortage Area in USA

    Dec 1, 2022, 00:00

  • EE442 Care Costs of Non-Small Cell Lung Cancer, Colorectal Cancer, and Thyroid Cancer in Turkiye: A Delphi Panel Study

    Dec 1, 2022, 00:00

  • EPH35 Post-COVID Conditions in Hospitalized COVID-19 Patients in Germany

    Dec 1, 2022, 00:00

  • EE545 Mapping Between Health and Broader Quality of Life Instruments: A Scoping Review

    Dec 1, 2022, 00:00

  • RWD146 Economic Burden Associated With Streptococcus Suis Infection Treatment in Northern Thailand: A Hospital-Based Observational Study

    Dec 1, 2022, 00:00

  • HSD103 Evolution 2019-2020 of Immune Checkpoint Inhibitors (ICI) Administration in Hospitalization at Home (HAH) for Cancer Patients in Fran Descriptive Analysis From the French Public Health Insurance Database (PMSI)

    Dec 1, 2022, 00:00

  • RWD76 Real-World Patient Persistence and Complian A Comparison of Prostaglandin Analogs Used for the Treatment of Open-Angle Glaucoma or Ocular Hypertension

    Dec 1, 2022, 00:00

  • CO78 Matching-Adjusted Indirect Comparison of Futibatinib Versus Chemotherapy and Pemigatinib in Cholangiocarcinoma Patients With FGFR2 Fusions/Rearrangements

    Dec 1, 2022, 00:00

  • EE82 Early Economic Modelling of Cancer Therapy

    Dec 1, 2022, 00:00

  • HPR75 An Analysis of Special Pricing Arrangements (SPAS) Between 2013 and 2021 in Australia

    Dec 1, 2022, 00:00

  • EE568 Tenecteplase or Alteplase for Acute Ischemic Stroke? A Cost-Effectiveness Analysis

    Dec 1, 2022, 00:00

  • PCR163 Humanistic and Economic Burden of Pyruvate Kinase Deficiency: A Systematic Review of Literature

    Dec 1, 2022, 00:00

  • SA48 Identifying Flares in Lupus Nephritis Patients by Combining Structured and Unstructured Medical Records With Lab Data

    Dec 1, 2022, 00:00

  • HTA9 The Benefits That a Novel Antimicrobial Provides When Viewed From an Insurance Value Perspective

    Dec 1, 2022, 00:00

  • MSR69 Challenges in Presenting Engagement Statistics in Real-World Digital Studies

    Dec 1, 2022, 00:00

  • HTA18 Impact of The Use of Cost-Effectiveness Analysis (CEA) on Patient Access to Medicines: A Comparison of CEA vs Non-CEA Markets

    Dec 1, 2022, 00:00

  • EE591 Economic Modeling Considerations for Rare Neurodegenerative Diseases of Infancy and Early Childhood

    Dec 1, 2022, 00:00

  • EPH13 Modelling the Impact on Lung Cancer Life Years of Universal Screening for Lung Cancer Amongst Defined High-Risk Populations in Greece

    Dec 1, 2022, 00:00

  • HTA160 A Systematic Review and Meta-Analysis of the Janus Kinase Inhibitors Safety Profile in Relation to the Risks of Secondary Bacterial Infections

    Dec 1, 2022, 00:00

  • PCR8 Exploring Preferences of Different Modes of Administration of Hypomethylating (HMA) Treatments Among Patients With Acute Myeloid Leukemia (AML)

    Dec 1, 2022, 00:00

  • EE524 The Incremental Cost-Effectiveness Ratio (ICER) Thresholds in Central and Eastern European Countries

    Dec 1, 2022, 00:00

  • HPR33 Price Erosion for Haemato-Oncology Drugs in European Markets

    Dec 1, 2022, 00:00

  • EPH113 Influence of an Intervention to Inform Mothers About Breastfeeding Using a Logistic Regression Model: Should We Invest Into Breastfeeding Education in France?

    Dec 1, 2022, 00:00

  • EE120 Real-World Utilisation of Damoctocog Alfa Pegol in Adults With Haemophilia A: Second Interim Analysis of the HEM-POWR Observational Study

    Dec 1, 2022, 00:00

  • EE276 The Budget Impact of Introducing a Rapid Polymerase Chain Reaction Test for the Detection of Influenza and Respiratory Syncytial Virus in China

    Dec 1, 2022, 00:00

  • HPR35 Are the Sales Forecast for Medical Devices Accurate? A Retrospective Analysis in France (2018-2021)

    Dec 1, 2022, 00:00

  • HPR101 Analyzing Substitution Effects in Financing of the Pharmaceutical Sector in Greece

    Dec 1, 2022, 00:00

  • HPR201 Combination Policy – Value of Combination Treatments and the Future in Cancer Management

    Dec 1, 2022, 00:00

  • CO160 Dependence Levels Derived From the Alzheimer's Disease Cooperative Study – Activities of Daily Living in People With Early (Prodromal-to-Mild) Alzheimer's Disease

    Dec 1, 2022, 00:00

  • EPH74 Mortality From Ischaemic Heart Disease Among Women in Hungary by County

    Dec 1, 2022, 00:00

  • CO109 What Does Real World Evidence Tells? A Case Analysis in Breast Cancer Using Pharmaceutical Consultation Data

    Dec 1, 2022, 00:00

  • PCR11 Quality of Life Analysis of Hypoglossal Nerve Stimulation with INSPIRE® Device in the Treatment of Patients With Obstructive Sleep Apnea Intolerant to Continuous Positive Airway Pressure Therapy

    Dec 1, 2022, 00:00

  • EPH125 Potential Health Effects of a Blood-Based Genomic Test Used to Prescreen Individuals Eligible for Lung Cancer Screening in the U.S.

    Dec 1, 2022, 00:00

  • EE669 Use of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in the Spanish Hospital Setting: A Comparative Cost Analysis

    Dec 1, 2022, 00:00

  • EE40 Cost-Effectiveness of GLP-1 Receptor Agonists Versus Long-Acting Insulins in Type 2 Diabetes From the Healthcare Sector Perspective: A Model-Based Analysis Using Real-World Data

    Dec 1, 2022, 00:00

  • RWD27 Access to Social Security Among Multiple Sclerosis Patients in Italy

    Dec 1, 2022, 00:00

  • EE247 Public Health Impact of Switching From a Trivalent to a Quadrivalent Inactivated Influenza Vaccine in the Dominican Republic

    Dec 1, 2022, 00:00

  • MSR77 Bayesian Hierarchical Model-Based Network Meta-Analysis to Overcome Survival Extrapolation Challenges Caused by Immature Data: Application in Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) PD-L1>1%

    Dec 1, 2022, 00:00

  • PCR146 Preferences for Toenail Onychomycosis Treatments Among Canadians With and Without Diabetes Mellitus: A Discrete Choice Experiment

    Dec 1, 2022, 00:00

  • MSR104 Assessing the Impact of Integrating Extrapolated Long-Term Outcomes Into Elicitation of Unreported Subgroup-Specific Survival in Randomized Controlled Trials (RCTS): Insights From Advanced Stage Gastrointestinal Cancers

    Dec 1, 2022, 00:00

  • CO139 Augmenting Atrial Fibrillation Risk Prediction Tools – How Does Risk Differ by Prior Stroke Type?

    Dec 1, 2022, 00:00

  • EE145 Cost-Effectiveness Analysis of the Novel Powered Circular Stapler in Colorectal Anastomosis Surgery

    Dec 1, 2022, 00:00

  • RWD56 Machine Learning for Clustering Dyslipidemia Patients With Statin Intolerance in Germany

    Dec 1, 2022, 00:00

  • MSR85 Performance Comparison of Unanchored Matching-Adjusted Indirect Comparison and Naïve Treatment Indirect Comparison on Survival Outcomes: A Simulation Study

    Dec 1, 2022, 00:00

  • EE295 Indirect Treatment Comparison and Cost-Minimization Analysis of Riociguat Versus Selexipag in Patients With Pulmonary Arterial Hypertension

    Dec 1, 2022, 00:00

  • HPR38 A Quantitative Assessment of Reimubursement and Existing Price Levels for Multiple Myeloma Patient Across US, EU, CA Emerging Markets

    Dec 1, 2022, 00:00

  • PCR39 Family Crises and Coping Mechanisms

    Dec 1, 2022, 00:00

  • EPH11 Modeling the Public Health Impact of a Universal Rotavirus Program in the Netherlands

    Dec 1, 2022, 00:00

  • RWD142 General Vaccine Dispensing Patterns During the First Year of the COVID-19 Pandemic in South Africa

    Dec 1, 2022, 00:00

  • PCR194 What Can We Learn From One Million Completed Daily Questionnaires About Patient Compliance and Burden?

    Dec 1, 2022, 00:00

  • HSD42 Modelling Time and Costs Associated With Daratumumab Treatment Delivery in the Home Care Setting Versus the Hospital in Spain to Understand Potential Benefits to Patients and Hospitals

    Dec 1, 2022, 00:00

  • HTA21 Evolving Landscapes for Advanced Therapy Medicinal Products (ATMPS): Access in the US, UK, EU

    Dec 1, 2022, 00:00

  • SA10 Systematic Literature Review of Randomized Clinical Trials (RCTS) on Ivabradine (IVA) in Heart Failure (HF)

    Dec 1, 2022, 00:00

  • EE20 Cost-Minimization Analysis for Treating T1DM and T2DM With Toujeo in Turkiye

    Dec 1, 2022, 00:00

  • HTA148 PRIME: Does Accelerated Marketing Authorization Translate Into Expedited Reimbursement and Patient Access?

    Dec 1, 2022, 00:00

  • MSR107 Can Artificial Intelligence (AI) Be Used to Improve the Efficiency of Title and Abstract Citation Screening?

    Dec 1, 2022, 00:00

  • HTA257 MOVe-OUT: A Trial of Two Halves – The Impact of Heterogeneity on Cost-Effectiveness Outcomes for COVID-19

    Dec 1, 2022, 00:00

  • HPR195 Assessing the Adoption of Sustainability Criteria Within National Healthcare Procurement Policies in Europe

    Dec 1, 2022, 00:00

  • CO135 Matching-Adjusted Indirect Comparison of Risdiplam Versus Nusinersen in Type 1 Spinal Muscular Atrophy: 2-Year Update

    Dec 1, 2022, 00:00

  • EE2 Health Outcome in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated With First-Line Sintilimab Plus Cisplatin and Paclitaxel Versus Cisplatin and Paclitaxel

    Dec 1, 2022, 00:00

  • P4 Cost Analysis of Post-COVID-19 Healthcare Consumption in the Netherlands

    Dec 1, 2022, 00:00

  • EE566 Cost-Effectiveness and Budget Impact Analysis of Selective Internal Radiation Therapy Versus Atezolizumab Plus Bevacizumab From a German Statutory Health Insurance Perspective

    Dec 1, 2022, 00:00

  • OP13 Drug Shortage Concepts Among Stakeholders in Saudi Arabia

    Dec 1, 2022, 00:00

  • EE646 Systematic Review on Cost and Healthcare Resource Utilization in Immunoglobulin A Nephropathy (IgAN)

    Dec 1, 2022, 00:00

  • MSR139 Safe to Assume? Unpacking Regression Assumptions for Utility Data

    Dec 1, 2022, 00:00

  • EE63 Economic Burden of Respiratory Syncytial Virus in Adults in the United States

    Dec 1, 2022, 00:00

  • RWD110 Real World Outcomes in Patients with Advanced/Metastatic Solid Tumors Who Are Immuno-Oncology (IO) Naive and Received Second-Line Therapy: Analysis by Tumor Mutational Burden (TMB) Status

    Dec 1, 2022, 00:00

  • PCR220 Attitude Toward HPV Vaccination Among Mothers of Boys and Girls

    Dec 1, 2022, 00:00

  • HTA118 Cost-Effectiveness of Pressured-Controlled Intermittent Coronary Sinus Occlusion in ST-Elevated Myocardial Infarction: A Threshold Analysis for Italy on the Cost of the Device

    Dec 1, 2022, 00:00

  • RWD83 Real-World Treatment Patterns in Chronic Spontaneous Urticaria in the United States

    Dec 1, 2022, 00:00

  • EE195 Economic Burden of Cardiovascular Disease Among Commercially Insured Adults Diagnosed With Colorectal Cancer in the United States

    Dec 1, 2022, 00:00

  • EPH31 Risk of Hospital Admission or Emergency Department Presentation Due to Diabetes Complications: A Retrospective Cohort Study in Tasmania, Australia

    Dec 1, 2022, 00:00

  • EE348 The Cost-Effectiveness of Belimumab for the Treatment of Patients With Systemic Lupus Erythematosus (SLE) in China

    Dec 1, 2022, 00:00

  • RWD74 Real-World Effectiveness of CDK 4/6 Inhibitor as First-Line Treatment in Patients With HR+, HER2- Advanced Breast Cancer in South Korea - Focused on Underrepresented Younger and Older Age

    Dec 1, 2022, 00:00

  • HPR100 Analysis of the Drug Price Level of Anticancer and Rare Disease Drugs After the Implementation of Economic Evaluation Exemption in South Korea

    Dec 1, 2022, 00:00

  • EPH128 Hospitalizations for Post-Chemotherapy Red Blood Cell Transfusions in France, 2017–2020

    Dec 1, 2022, 00:00

  • CO96 Real-World (RW) Use of Cladribine Tablets in Portugal: A Two-Year Update of a Cohort Database

    Dec 1, 2022, 00:00

  • MT10 Is Ethnicity an Effect Modifier Between FLT3 Inhibitors and Salvage Therapy for Relapsed and Refractory Acute Myeloid Leukemia?

    Dec 1, 2022, 00:00

  • HTA215 Comparison of French HTA Parallel Appraisal Performed by the Economic and Public Health Committee (CEESP) and the Transparency Committee (TC) for a Same Product: Are the Conclusions of the Two Committees Consistent?

    Dec 1, 2022, 00:00

  • EE426 Budget Impact Analysis of Atezolizumab in 1ST Line Treatment for Patients With PD-L1 High Metastatic NSCLC From a French Payor Perspective

    Dec 1, 2022, 00:00

  • EE464 Is the Willingness to Pay for Years of Life in an Extreme Situation of the COVID Pandemic Closures Similar to the Willingness to Pay in Situations of Ordinary Basis? Comparison by Population Groups

    Dec 1, 2022, 00:00

  • MSR41 Predicting Antimicrobial Resistance in Uncomplicated Urinary Tract Infections Using Machine Learning

    Dec 1, 2022, 00:00

  • EE370 Cost Effectiveness Evaluation of Dapagliflozin in the Treatment of Chronic Kidney Disease in Mexico

    Dec 1, 2022, 00:00

  • EPH23 An Epidemiological Estimate of the Prevalence of the Coded Nonalcoholic Steatohepatitis (NASH) Population in the US Using an Administrative Claims Dataset

    Dec 1, 2022, 00:00

  • EPH133 Cross-Sectional Research on the Development of Case Management Approach for Disability Patient Based on the Workability Index and Quality of Life Measures

    Dec 1, 2022, 00:00

  • HTA177 Current Developments in the Market Access Conditions for Gene Therapies in Germany

    Dec 1, 2022, 00:00

  • PCR36 Content Validity, Acceptability, and Usability of the Electronic Hidradenitis Suppurativa Symptom Daily Diary and the Electronic Hidradenitis Suppurativa Symptom Questionnaire

    Dec 1, 2022, 00:00

  • HTA264 Why Doesn't Environmental Impact Play a Bigger Role in Health Economic Evaluation and Health Technology Assessment – A Systematic Literature Review

    Dec 1, 2022, 00:00

  • EE664 The Basis for a New Framework to Determine the Cost-Effectiveness Threshold

    Dec 1, 2022, 00:00

  • CO173 Efficacy and Safety of Daridorexant in Patients With Insomnia: Systematic Review Meta-Analysis of Randomized Controlled Trials

    Dec 1, 2022, 00:00

  • HTA182 Time to Access Pediatric/Adolescent vs Adult Medicinal Products in Greece

    Dec 1, 2022, 00:00

  • EE628 Economic Benefits of Cangrelor in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • HPR203 Terminated NICE Appraisals – A Hidden Driver Behind the UK's Access Challenges?

    Dec 1, 2022, 00:00

  • EPH5 Impact of the COVID-19 Pandemic on Cervical and Breast Cancer Screening

    Dec 1, 2022, 00:00

  • HPR118 An Updated Estimate of the Direct Cost of the COVID-19 Pandemic for the Greek Healthcare System

    Dec 1, 2022, 00:00

  • EE242 Cost-Effectiveness Analysis of Entrectinib for Treatment NTRK Fusion-Positive Tumors in Czech Republic

    Dec 1, 2022, 00:00

  • PCR281 Utility Studies in Rare Diseases: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • EE390 Cost-Effectiveness of the 20-Valent Pneumococcal Conjugate Vaccine vs 15-Valent Pneumococcal Conjugate Vaccine for Adults in Argentina

    Dec 1, 2022, 00:00

  • EE260 An Early Cost-Effectiveness Analysis of a New Continuous Compartment Pressure Monitoring Device in Tibial Fracture Patients Who Are at Risk of Developing Acute Compartment Syndrome (ACS)

    Dec 1, 2022, 00:00

  • EE290 Cost-Effectiveness of Intravenous Iron Formulations in Patients With Iron Deficiency Anaemia and IBD in Sweden

    Dec 1, 2022, 00:00

  • PCR271 Health-Related Quality of Life (HRQOL) by Line of Treatment, Treatment History, and Disease Status in Patients With Metastatic Urothelial Carcinoma (MUC) in EU-4 and the United Kingdom: Results From a Disease Specific Programme

    Dec 1, 2022, 00:00

  • HSD91 Introducing Time-Driven Activity-Based Costing in Chile: Medium Costs Estimation of Breast Cancer Biopsies in a Public Anatomic Pathology Laboratory

    Dec 1, 2022, 00:00

  • MSR64 Utility Analysis Methods: Can One Method Fit It All or Is a Case-By-Case Approach Required?

    Dec 1, 2022, 00:00

  • CO77 Use of Interrupted Time-Series Analyses in Evaluating Health Economic Outcomes Following Implementation of Multilayer Water-Tight Wound Closure in a Primary Total Joint Arthroplasty Population

    Dec 1, 2022, 00:00

  • HTA144 Evolution and Implications of the Portuguese HTA Framework on Added Therapeutic Value in Patients’ Access to Innovation

    Dec 1, 2022, 00:00

  • EPH102 Public Health Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in Chile

    Dec 1, 2022, 00:00

  • EE61 Economic Evaluation of Therapies Submitted With Non-Comparative Single Arm Phase II Data: A Comparison of NICE and Has Efficiency Opinions

    Dec 1, 2022, 00:00

  • RWD129 A Comparison of ICU Admission Rate and Related Cost Among Patients Taking Nirmatrelvir and Ritonavir Combination Versus Molnupiravir for Treatment of Mild to Moderate COVID-19 in the US

    Dec 1, 2022, 00:00

  • PCR222 Quality of Life (QOL) in Patients With Depression– A Review of Patient Reported Outcomes Instruments

    Dec 1, 2022, 00:00

  • HPR167 A Comparison of ICER Health-Benefit Price Benchmarks in the United States to Drug Prices in the United Kingdom and France

    Dec 1, 2022, 00:00

  • HTA15 An Evaluation of Health Technology Assessment (HTA) Requirements for Emerging Therapies in Alzheimer’s Disease (AD)

    Dec 1, 2022, 00:00

  • EE252 Budget Impact of a Minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia in Spain

    Dec 1, 2022, 00:00

  • EE480 Cost-Effectiveness of Empagliflozin for the Treatment of Patients With Heart Failure With Above 40% Ejection Fraction in England

    Dec 1, 2022, 00:00

  • HTA19 How Are United States ICER’S Evidence Ratings Determined? A Systematic Review of ICER’S Evidence Ratings in Evidence Reports for New Drugs in 2020 and 2021

    Dec 1, 2022, 00:00

  • HTA44 Utilisation of Societal Costs in the NICE HST Approvals Compared to European Agencies

    Dec 1, 2022, 00:00

  • EE272 A Pragmatic Literature Review on the Economic Cost Burden of Four Key Preventable Diseases in the UK

    Dec 1, 2022, 00:00

  • HPR202 Use of Real-World Data in Regulatory and Reimbursement Submissions for Personalized Medicines in Europe

    Dec 1, 2022, 00:00

  • HPR190 Evaluating the Impact of the Entry of IVD-R in the Biopharmaceutical Industry, With a Focus on Evidence Requirements and Time to Launch

    Dec 1, 2022, 00:00

  • EE8 Cost of Arthropathic Diseases Therapy: A 5-Year Budget Analysis at National Level

    Dec 1, 2022, 00:00

  • CO79 Post-Acute Myocardial Infarction: 90-Day Outcomes Assessment Becoming More Relevant and Critical Due to Patient Burden and Poor Outcomes

    Dec 1, 2022, 00:00

  • MT8 A Systematic Literature Review of Published Economic Evaluations for Medical Devices in Cardiovascular Disease

    Dec 1, 2022, 00:00

  • EE300 Health Care Resource Utilisation (HCRU) and Corresponding Costs of Respiratory Syncytial Virus (RSV) Admissions Before the Age of Two in England

    Dec 1, 2022, 00:00

  • MSR137 The Impact of the Proportion of Cured and Length of Follow-up on Mixture Cure Models (MCMS): A Simulation Study

    Dec 1, 2022, 00:00

  • RWD15 A Retrospective Database Study to Describe the Prevalence, Patient Characteristics and Healthcare Burden of Prurigo Nodularis (PN) in England

    Dec 1, 2022, 00:00

  • EE211 Shadow Costs of Systemic Corticosteroid-Related Adverse Events in Ulcerative Colitis: A Pharmacoeconomic Evaluation

    Dec 1, 2022, 00:00

  • PCR173 Patient and Carer Involvement (PI) in Real World Data Evidence Generation (RWDEG): Findings From Industry

    Dec 1, 2022, 00:00

  • HTA1 Accounting for Placebo Effects in NICE Technology Appraisals of Biologic Therapies: A Comprehensive Review and Future Recommendations

    Dec 1, 2022, 00:00

  • EE678 Cost Effectiveness of Cognitive Behavioural Therapy for Psychosis Through Reduced Hospitalisation

    Dec 1, 2022, 00:00

  • Deciding Between SF-6Dv2 Health States: A Think-Aloud Study of Decision-Making Strategies Used in Discrete Choice Experiments

    Dec 1, 2022, 00:00

  • HPR110 ESG in Pharma Procurement, Not More Than Wishful Thinking? A Quantitative View on Award Criteria in Tenders in the EU5 From 2011 to 2020

    Dec 1, 2022, 00:00

  • MT43 Evidence Generation of Digital Health Applications in Germany – An Overview of the Status Quo

    Dec 1, 2022, 00:00

  • SA65 Future Prophylaxis Strategies in RSV: End of the Status Quo

    Dec 1, 2022, 00:00

  • MSR25 To Merge Randomized Controlled Trials and Real-World Evidence With Bayesian Network Meta-Regression: A Case Study in Patients With Myelodysplastic Syndromes

    Dec 1, 2022, 00:00

  • HTA169 Health Technology Assessment and Reimbursement for Select Oncology Therapies in European Major Markets

    Dec 1, 2022, 00:00

  • EPH142 The Burden of Metastatic or Inoperable HER2+ Breast Cancer on the Italian Health System

    Dec 1, 2022, 00:00

  • EE466 Budget Impact Analysis of Cemiplimab for First-Line (1L) Advanced Non-Small Cell Lung Cancer (NSCLC) With Programmed Cell Death-Ligand 1 (PD-L1)≥ 50% in Italy

    Dec 1, 2022, 00:00

  • MT23 Use of Real Time Chat Functionality in Decentralized Clinical Trials

    Dec 1, 2022, 00:00

  • EPH28 Underage Drinking in Adolescents

    Dec 1, 2022, 00:00

  • PCR38 To What Extent Are Long-Term Breast Cancer Survivors Subjected to Financial Burden in Germany? Results From a Patient Survey-Based Study

    Dec 1, 2022, 00:00

  • EE347 Treatment Patterns and Healthcare Resource Utilization (HRU) Among Patients With Multiple Sclerosis (MS) in Germany Treated With Nabiximols Between 2010 and 2020

    Dec 1, 2022, 00:00

  • MSR111 Methodology for Building Physician Target List Using Claims and EHR Data

    Dec 1, 2022, 00:00

  • EE224 Cost-Effectiveness Analysis of Real-Time Continuous Glucose Monitoring (RTCGM) vs Self-Monitoring of Blood Glucose (SMBG) in Patients With Type 1 Diabetes in the Netherlands

    Dec 1, 2022, 00:00

  • RWD18 Underappreciation of Disease Burden in Female Patients With Axial Spondyloarthritis (AxSpA) in Real-World Care

    Dec 1, 2022, 00:00

  • HPR196 Patient Reported Outcome Measures Are of Profound Importance for the Success of Health Technology Assessments in Oncologic Indications in Germany

    Dec 1, 2022, 00:00

  • HTA189 Implications of the French Temporary Authorisation for Use Reform for the Pharma Industry

    Dec 1, 2022, 00:00

  • SA38 Mortality Estimates in Patients With Anti-Aquaporin-4 Autoantibody Positive Neuromyelitis Optica Spectrum Disorder

    Dec 1, 2022, 00:00

  • HPR213 Comparative Analysis of Access to Advanced Therapy Medicine Products (ATPM) in Latin America

    Dec 1, 2022, 00:00

  • EE431 The Cost-Effectiveness of Home-Based Cardiac Rehabilitation Interventions: A Systematic Review

    Dec 1, 2022, 00:00

  • HPR113 Health Metrics and Theories of Health Value

    Dec 1, 2022, 00:00

  • HTA150 RWE in HTA Recommendations for Decision Making: Analysis From Ukrainian Perspective

    Dec 1, 2022, 00:00

  • EPH93 Drivers of Treatment Decisions in Multiple Myeloma Front-Line Transplant-Eligible Patients in a Real-World Setting: A Qualitative Assessment of Physicians’ Perspectives in Europe

    Dec 1, 2022, 00:00

  • EE358 Efficiency of Third-Generation Antiseizure Medications in Spain for Drug-Resistant Epilepsy: A Cost-per-Number Needed to Treat Analysis

    Dec 1, 2022, 00:00

  • EE394 Cost-Effectiveness of Alpelisib Plus Fulvestrant for the Treatment of Postmenopausal Women With PIK3CA Mutant, HR+/HER2- Advanced Breast Cancer in Turkey

    Dec 1, 2022, 00:00

  • MSR34 Forecasting the Long-Term Treatment Effect Duration of Immuno-Oncology Therapies: An Analysis of the Predictive Accuracy of Treatment Waning Methods Applied to Pembrolizumab in Non-Small Cell Lung Cancer

    Dec 1, 2022, 00:00

  • HPR147 Evaluating the Misdiagnosis of Add in Patients With Prior History of Depression: A Claims Data Study in Germany

    Dec 1, 2022, 00:00

  • EPH145 Treatment Patterns Among Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Ineligible for Transplantation – A Real-World Study Using French PMSI

    Dec 1, 2022, 00:00

  • HTA161 A Systematic Review of the Safety of COVID-19 Anti-Interleukin Therapy

    Dec 1, 2022, 00:00

  • HTA234 Impact of Cost-Effectiveness Assessment Scheme (as a Part of HTA System) on Drug Prices in Japan

    Dec 1, 2022, 00:00

  • PCR57 An Empirical Comparison of Data From Forced vs Non-Forced Choices in a Dual Response Discrete Choice Experiment, With Breast Cancer Patients in Six European Countries

    Dec 1, 2022, 00:00

  • EE363 Long Term Costs Assessment of Oral Therapies for Patients With Relapsing Multiple Sclerosis Based on the Evidence From a Large Real-World Study – Application to a Portuguese National Academic Hospital Center

    Dec 1, 2022, 00:00

  • PCR261 Elicitation of Health Utilities Online in Patients With Spinal Muscular Atrophy

    Dec 1, 2022, 00:00

  • EE498 Cost of Follow-Up After an Ischemic Cerebrovascular Event in Patients With Atherosclerotic Cardiovascular Disease in Spain: Results from the Reality Study

    Dec 1, 2022, 00:00

  • EPH190 Premature Mortality From Ischaemic Heart Disease Among Men in Hungary by District

    Dec 1, 2022, 00:00

  • PCR27 Pediatric Outcomes Data Collection Instrument (PODCI) Assessment of Ambulatory Boys Treated With Fordadistrogene Movaparvovec (PF-06939926) for Duchenne Muscular Dystrophy (DMD)

    Dec 1, 2022, 00:00

  • PCR162 Patient and Physician Perspectives Towards Current HIV Treatment Satisfaction and the Use of Long-Acting Injectable Therapy for HIV in Taiwan

    Dec 1, 2022, 00:00

  • EPH106 Evaluating Changes in the Diagnostic Setting and Treatment of Bacterial Sexually Transmitted Infections in Germany During COVID-19: A Descriptive Analysis of German Claims Data From 2018-2021

    Dec 1, 2022, 00:00

  • HPR140 Assessing the Influence of the Orphan Drug Status on Medicine Prices in the EU4 + UK

    Dec 1, 2022, 00:00

  • PCR52 Adherence/Compliance to HIV–1 Treatment Regimens in South Africa — A Targeted Literature Review

    Dec 1, 2022, 00:00

  • CO169 Assessing Parameters and Microbiological Factors Affecting Phlebitis Associated With Peripheral Cannulas

    Dec 1, 2022, 00:00
  • «
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37 (current)
  • 38
  • 39
  • 40
  • »